Biosergen AB

As of June 30, 2026, Biosergen AB carries a market capitalization of 11.32M, placing it among publicly traded companies globally. Its enterprise value stands at 8.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biosergen AB's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Biosergen AB has 21.44M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Biosergen AB maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Biosergen AB's stock has declined approximately 90.94% over the past 52 weeks. The 50-day moving average sits at 1.16, while the 200-day moving average is 2.06.

These figures are as of June 30, 2026. Total book value stands at 704,000.00, with working capital of 703,000.00 providing operational flexibility.

Biosergen AB's most recent stock split took place on August 7, 2026 with a 23:210 split ratio.